Briefly, secondary objectives include assessment of patient outcomes (90 day mortality, readmission rate and hospital length of stay); assessment of diagnostic accuracy of brain-natriuretic peptide for heart failure and both C-reactive protein and procalcitonin for respiratory infections (such as pneumonia). This evidence concerns the gene NPPB and pneumonia.